Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70 Read more about Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70
European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer Read more about European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer
Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference Read more about Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma Read more about FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer Read more about Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer
Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology Read more about Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology
Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan Read more about Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha™ (evolocumab) In Japan
Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology Read more about Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology
Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine Read more about Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (evolocumab) In The New England Journal of Medicine
